2,5-Disubstituted pyridines: The discovery of a novel series of 5-HT2A ligands

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 9, 2007, Pages 2643-2648

  Wilson, Kevin J ^a   van Niel, Monique B ^a   Cooper, Laura ^a   Bloomfield, Dawn ^a   O'Connor, Desmond ^a   Fish, L Rebecca ^a   MacLeod, Angus M ^a  

^a NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

Author keywords

5 HT2A ligand; Pyridine; Styrene

Indexed keywords

ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; AMINE; AROMATIC COMPOUND; EMD 281014; LIGAND; PYRIDINE DERIVATIVE; RECEPTOR SUBTYPE; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG TARGETING; ISOMER; NONHUMAN; RAT; RECEPTOR AFFINITY; RECEPTOR OCCUPANCY; STRUCTURE ACTIVITY RELATION;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; HUMANS; KINETICS; LIGANDS; MODELS, CHEMICAL; MOLECULAR CONFORMATION; PYRIDINES; RATS; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN ANTAGONISTS; SULFONES;

EID: 34047114056     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.01.098     Document Type: Article

References (17)

1. Ohayon M.M. Sleep Med. Rev. 6 (2002) 97
2. Taylor D.J., Lichstein K.L., Durrence H., Reidel B.W., and Bush A.J. Sleep 28 11 (2005) 1457
3. Mendelson W.B., Roth T., Cassella J., Roehrs T., Walsh J.K., Woods J.H., Buysse D.J., and Meyer R.E. Sleep Med. Rev. 8 (2004) 7 and references cited within
4. Holbrook A.M., Crowther R., Lotter A., Cheng C., and King D. Can. Med. Assoc. J. 162 2 (2000) 225
5. Hajak G., Muller W.E., Wittchen H.U., Pittrow D., and Kirch W. Addiction 98 (2003) 1371
6. Idzikowski C., Mills F.J., and Glennard R. Brain Res. 378 (1986) 164
7. Markham, R. J. Aventis 2003 Press and Analyst Conference, London, UK, February 2004.
8. Fish L.R., Gilligan M.T., Humphries A.C., Ivarsson M., Ladduwahetty T., Merchant K.J., O'Connor D., Patel S., Philipps E., Vargas H.M., Hutson P.H., and MacLeod A.M. Bioorg. Med. Chem. Lett. 15 (2005) 3665
9. Fletcher S., Burkamp F., Blurton P., Cheng S.K.F., Clarkson R., O'Connor D., Spinks D., Tudge M., van Niel M.B., Patel S., Chapman K., Marwood R., Shepheard S., Bentley G., Cook G.P., Bristow L.J., Castro J.L., Hutson P.M., and MacLeod A.M. J. Med. Chem. 45 (2002) 492
10. Ladduwahetty T., Boase A.L., Mitchinson A., Quin C., Patel S., Chapman K., and MacLeod A.M. Bioorg. Med. Chem. Lett. 16 (2006) 3201
11. Westkaemper R.B., and Glennon R.A. Curr. Top. Med. Chem. (2002) 575
12. The evolution and optimization of the related phenylsulfones will be discussed in detail in a separate publication.
13. Kwong F.K., and Buchwald S.L. Org. Lett. 4 (2002) 3517
14. ® microwave reactor from Personal Chemistry.
15. 6) 6.16 (1H, d, J = 18.6 Hz), 7.11 (1H, m), 7.25 (1H, m), 7.34 (1H, d, J = 18.6 Hz), 7.68 (1H, m), 7.87 (2H, s).
16. 3H] radioligand (6 μCi) was administered by tail vein injection. Full assay details are described in Ref. 8.
17. 2A receptor was calculated using the following equation: Total binding (TB) = Vehicle counts; Compound binding (CB) = Compound counts; Occupancy (%) = 100-[100 × (CB/TB)].